PositiveID Corp (OTCMKTS:PSID) has placed another patent application for its handheld biological detection device known as Firefly Dx, a real-time PCR (polymerase chain reaction) pathogen detection solution. The company said that it would continue to file for more patents as development and test of the diagnostic system progresses.
18 patents and patent applications
Together with the latest patent filing, PositiveID Corp (OTCMKTS:PSID) currently has four patents and patents pending for its Firefly Dx technology. Overall, the company has 18 patents and patent applications.
Firefly Dx is a breakthrough diagnostic solution, which in addition to real-time testing, also supports accurate diagnostic results based on PCR chemistry. The handheld device supports delivers biologic test at the point of need in ways that are superior to existing diagnostic systems.
More efficient biological test
Firefly Dx is able to provide test results in less than 20 minutes, making it far more efficient compared to lab-based equipment that could take up to several hours of days before providing results. PositiveID Corp (OTCMKTS:PSID)’s latest patent application for Firefly Dx describes a device that is able to offer test results in less than 20 minutes while still being able to use the standard lab processes and volumes.
$27.4 billion market
PositiveID Corp (OTCMKTS:PSID) is targeting the global PCR market with its Firefly Dx device. According to market projections, the global market for PCR solutions is expected to reach about $27.4 billion in 2015.
Point of need testing
PositiveID Corp (OTCMKTS:PSID)’s real-time biological test solution, Firefly Dx, is suitable for test at locations such as airports to support speedy screening for biological threats such as Ebola, Dengue Fever and influenza.
When Ebola broke out in West Africa, one of the major challenges that healthcare providers faced was the longer periods it takes to diagnose the deadly virus. Speedy test enhances treatment and also helps with curbing the spread of infections diseases such as Ebola. Firefly Dx could be a perfect fit to address the need for emergency biological testing.
